Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 43%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics is seeing strong financial performance and many upcoming milestone payments, with a forecasted runway through at least 2028. The recent approval and launch of Icotyde for psoriasis, as well as potential future approvals for other indications, could drive significant revenue and support the company's peptide platform and other pipeline programs. With multiple shots on goal and a strong cash balance, our outlook remains positive and our price target has increased from $112 to $118.

Bears say

Protagonist Therapeutics is facing a difficult road ahead with its Ico drug, as patient adoption rates and market expansion projections are heavily dependent on patient preference for biologics. Additionally, while their wholly owned programs are on track, their estimated timelines for completion and initiation of studies are pushed back, which could hinder potential revenue growth. Finally, their partnership with Takeda for Rusfertide provides a potential positive revenue stream in the future, but may not be enough to offset the challenges facing the company.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.